Source comparison
CJC-1295 30s Age Specific Protocol: Dosing vs Cycling Comparison
| Protocol Variable | Conservative (New to Peptides) | Moderate (Prior GH Secretagogue Use) | Aggressive (Experienced, Low Baseline IGF-1) | Professional Assessment ||—|—|—|—|| Dosing | 1mcg/kg twice weekly (e.g., 75mcg for 75kg researcher) | 1.5mcg/kg twice w
This comparison does not assign a generated winner or score.
- | Protocol Variable | Conservative (New to Peptides) | Moderate (Prior GH Secretagogue Use) | Aggressive (Experienced, Low Baseline IGF-1) | Professional Assessment ||—|—|—|—|| Dosing | 1mcg/kg twice weekly (e.g., 75mcg for 75kg researcher) | 1.5mcg/kg twice weekly (e.g., 112mcg for 75kg researcher) | 2mcg/kg twice weekly (e.g., 150mcg for 75kg researcher) | Start conservative. 30s retain enough pituitary responsiveness that higher doses rarely outperform moderate ones. Dose escalation should be IGF-1-driven, not arbitrary. || Cycle Length | 8 weeks on, 4 weeks off | 10 weeks on, 4 weeks off | 12 weeks on, 4–6 weeks off | Receptor desensitization begins around week 8–10 for most researchers in their 30s. Extending beyond 12 weeks increases the risk of diminished response without adding benefit. || Injection Frequency | Twice weekly (Monday/Thursday or Tuesday/Friday) | Twice weekly (same) | Twice weekly (same) | Twice-weekly dosing matches CJC-1295's 6–8 day half-life and preserves nat